JP2023539867A5 - - Google Patents
Info
- Publication number
- JP2023539867A5 JP2023539867A5 JP2023513510A JP2023513510A JP2023539867A5 JP 2023539867 A5 JP2023539867 A5 JP 2023539867A5 JP 2023513510 A JP2023513510 A JP 2023513510A JP 2023513510 A JP2023513510 A JP 2023513510A JP 2023539867 A5 JP2023539867 A5 JP 2023539867A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- treatment
- skp2
- mdm2
- mdm2 antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2013476.3A GB202013476D0 (en) | 2020-08-27 | 2020-08-27 | Cancer biomarkers |
| GB2013476.3 | 2020-08-27 | ||
| GB2020493.9 | 2020-12-23 | ||
| GBGB2020493.9A GB202020493D0 (en) | 2020-12-23 | 2020-12-23 | Cancer biomarkers |
| PCT/IB2021/057853 WO2022043930A2 (en) | 2020-08-27 | 2021-08-27 | Biomarkers for cancer therapy using mdm2 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539867A JP2023539867A (ja) | 2023-09-20 |
| JP2023539867A5 true JP2023539867A5 (enExample) | 2024-09-04 |
Family
ID=77595601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513510A Pending JP2023539867A (ja) | 2020-08-27 | 2021-08-27 | Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230313313A1 (enExample) |
| EP (1) | EP4204812A2 (enExample) |
| JP (1) | JP2023539867A (enExample) |
| KR (1) | KR20230058124A (enExample) |
| CN (1) | CN116194088A (enExample) |
| AU (1) | AU2021333983A1 (enExample) |
| CA (1) | CA3181715A1 (enExample) |
| TW (1) | TW202214248A (enExample) |
| WO (1) | WO2022043930A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CN112022812B (zh) * | 2020-11-03 | 2021-01-29 | 上海亚盛医药科技有限公司 | 一种包含杂环类化合物的组合物、其制备方法和应用 |
| CN114796227B (zh) * | 2022-05-30 | 2023-12-01 | 中山大学 | Ponatinib在制备预防或治疗血管退行性疾病药物中的应用及该药物 |
| WO2024097876A1 (en) * | 2022-11-02 | 2024-05-10 | Board Of Regents, The University Of Texas System | Methods relating to optimizing therapy selection for acute myeloid leukemia |
| TW202539630A (zh) * | 2023-11-16 | 2025-10-16 | 日商大塚製藥股份有限公司 | 包括ｍｄｍ２－ｐ５３抑制劑之醫藥組成物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| WO2000075184A1 (en) * | 1999-06-04 | 2000-12-14 | Yale University | Modulation of protein levels using the scf complex |
| UA107814C2 (uk) | 2009-11-12 | 2015-02-25 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Спірооксіндольні антагоністи мdм2 |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| EP2958893B1 (en) | 2013-02-21 | 2017-05-03 | F. Hoffmann-La Roche AG | Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| BR112015029976A2 (pt) | 2013-06-24 | 2017-07-25 | Hoffmann La Roche | formulação farmacêutica, formulação liofilizada farmacêutica e preparações novas, métodos e usos |
| SG11201510816SA (en) * | 2013-07-03 | 2016-01-28 | Hoffmann La Roche | Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist |
| KR20220136454A (ko) | 2013-09-04 | 2022-10-07 | 다이이찌 산쿄 가부시키가이샤 | 스피로옥시인돌 유도체의 제조 방법 |
| BR122022015241B1 (pt) | 2013-12-20 | 2023-09-26 | Astex Therapeutics Limited | Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i) |
| CA2945527C (en) | 2014-04-17 | 2022-05-17 | The Regents Of The University Of Michigan | Mdm2 inhibitors and therapeutic methods using the same |
| EP3206697A2 (en) * | 2014-10-17 | 2017-08-23 | Biomirna Holdings Ltd. | Lung cancer diagnostics and therapeutics with mir-660 |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| US10759808B2 (en) | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| SG11201808728QA (en) | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| WO2017205786A1 (en) | 2016-05-27 | 2017-11-30 | Aileron Therapeutics, Inc. | Cell permeable peptidomimetic macrocycles |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
-
2021
- 2021-08-27 EP EP21763416.1A patent/EP4204812A2/en active Pending
- 2021-08-27 JP JP2023513510A patent/JP2023539867A/ja active Pending
- 2021-08-27 TW TW110131860A patent/TW202214248A/zh unknown
- 2021-08-27 CA CA3181715A patent/CA3181715A1/en active Pending
- 2021-08-27 WO PCT/IB2021/057853 patent/WO2022043930A2/en not_active Ceased
- 2021-08-27 KR KR1020237010334A patent/KR20230058124A/ko active Pending
- 2021-08-27 CN CN202180050903.9A patent/CN116194088A/zh active Pending
- 2021-08-27 US US18/042,167 patent/US20230313313A1/en active Pending
- 2021-08-27 AU AU2021333983A patent/AU2021333983A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539867A5 (enExample) | ||
| Meyer et al. | Targeted quantification of C-reactive protein and cystatin c and its variants by immuno-MALDI-MS | |
| KR102442803B1 (ko) | 결장직장암에 대한 복합 테스트 | |
| JP2025111438A (ja) | イルジンおよびバイオマーカーを使用した固形腫瘍癌の治療方法 | |
| JP2021523379A5 (enExample) | ||
| Xu et al. | Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma | |
| CN110702917B (zh) | 血清淀粉样蛋白p在制备抑郁症诊断治疗相关产品的用途 | |
| JP2018529931A5 (enExample) | ||
| US20130210667A1 (en) | Biomarkers for Predicting Kidney and Glomerular Pathologies | |
| JP2023503379A5 (enExample) | ||
| Lipshitz et al. | Emerging markers of cancer cachexia and their relationship to sarcopenia | |
| JP5246709B2 (ja) | 自己免疫疾患検査用バイオマーカー及び検査方法 | |
| US20210230662A1 (en) | Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers | |
| Wang et al. | Combined analysis of serum SAP and PRSS2 for the differential diagnosis of CD and UC | |
| JP2008509411A (ja) | 肝線維症の診断方法 | |
| WO2010111892A1 (zh) | Angptl3作为卵巢癌的诊断标记物的用途 | |
| JP6046053B2 (ja) | Ｂｃｌ−２様タンパク質１１のＳＲＭ／ＭＲＭアッセイ | |
| JP5568807B2 (ja) | プロテオミクス解析を用いたメラノーママーカーの同定 | |
| CN108369233B (zh) | 基于标志物人附睾蛋白4 (he4)检测肺腺癌的复发的方法及相关用途 | |
| JP2012526543A5 (enExample) | ||
| Shin et al. | What is the appropriate cut-off value of CRP to predict endoscopic remission in patients with ulcerative colitis in clinical remission? | |
| Kusamura et al. | Expression of p53, c-erbB-2, Ki-67, and CD34 in granulosa cell tumor of the ovary | |
| AU2005258926A1 (en) | Biomarkers of Alzheimer's disease | |
| KR101913199B1 (ko) | 파브리병 진단용 바이오마커 및 이의 용도 | |
| WO2016014832A1 (en) | Biomarkers for assessment of preeclampsia |